{"id":"fak","name":"FAK (PTK2)","symbol":"PTK2","route":"/targets/fak/","asOf":"2026-09-22","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9611","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169398","uniprot":"https://www.uniprot.org/uniprotkb/Q05397/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q05397","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2695","open-targets":"https://platform.opentargets.org/target/ENSG00000169398","civic":"https://civicdb.org/genes/5747/summary","oncokb":"https://www.oncokb.org/gene/PTK2","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PTK2","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=PTK2","depmap":"https://depmap.org/portal/gene/PTK2?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000169398-PTK2","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/5747","omim":"https://www.omim.org/entry/600758"}],"products":[{"id":"avutometinib-defactinib","name":"Avutometinib + defactinib","status":"approved","modality":"Small-molecule RAF/MEK clamp + FAK inhibitor","route":"/drugs/avutometinib-defactinib/"},{"id":"gsk2256098","name":"GSK2256098","status":"phase-2","modality":"Oral focal adhesion kinase (FAK) inhibitor","route":"/drugs/gsk2256098/"},{"id":"in10018","name":"IN10018","status":"phase-3","modality":"small molecule","route":"/drugs/in10018/"}],"trials":[{"id":"nct07174908","name":"A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation","nct":"NCT07174908","phase":"3","status":"recruiting"},{"id":"nct07833202","name":"A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutatio","nct":"NCT07833202","phase":"3","status":"planned"},{"id":"ramp-201","name":"RAMP 201","nct":"NCT04625270","phase":"2","status":"positive"},{"id":"a071401","name":"Alliance A071401","nct":"NCT02523014","phase":"2","status":"positive"},{"id":"nct06014528","name":"IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurren","nct":"NCT06014528","phase":"2","status":"recruiting"},{"id":"nct06369259","name":"Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-R","nct":"NCT06369259","phase":"2","status":"recruiting"},{"id":"nct07126158","name":"Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma","nct":"NCT07126158","phase":"2","status":"recruiting"},{"id":"nct06166836","name":"a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors","nct":"NCT06166836","phase":"1/2","status":"active"},{"id":"nct06708663","name":"HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours","nct":"NCT06708663","phase":"1/2","status":"recruiting"},{"id":"nct05994131","name":"IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC","nct":"NCT05994131","phase":"1/2","status":"recruiting"},{"id":"nct06030258","name":"IN10018 Combination Therapy in Treatment-naïve ES-SCLC","nct":"NCT06030258","phase":"1/2","status":"recruiting"},{"id":"nct07441174","name":"IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors","nct":"NCT07441174","phase":"1/2","status":"recruiting"},{"id":"nct05551507","name":"IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer","nct":"NCT05551507","phase":"1/2","status":"recruiting"},{"id":"nct05827796","name":"IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer","nct":"NCT05827796","phase":"1/2","status":"recruiting"},{"id":"nct07824960","name":"Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma","nct":"NCT07824960","phase":"1/2","status":"planned"},{"id":"nct05379946","name":"Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors","nct":"NCT05379946","phase":"1/2","status":"active"}],"pathways":[],"companies":["gsk","inventisbio","inxmed","verastem"],"keyPapers":["paper-a071401-brastianos-jco-2023"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}